A U.S. biopharmaceutical company focused on antiviral therapies and specialty medicines, with leading franchises in HIV treatment and prevention. Its portfolio also includes therapies for hepatitis, oncology, and cell therapy developed through internal research and acquisitions. Investors closely wa...
6 members of Congress have disclosed 15 trades in Gilead Sciences, Inc. (GILD), a Healthcare company. The buy/sell breakdown shows 7 purchases versus 8 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2014-03-17 | JAMES B. RENACCI | sell | $1K – $15K |
| 2014-03-17 | JAMES B. RENACCI | sell | $1K – $15K |
| 2014-03-14 | JAMES B. RENACCI | buy | $1K – $15K |
| 2014-03-05 | JAMES B. RENACCI | buy | $15K – $50K |
| 2014-03-04 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2014-02-21 | Richard L. Hanna | buy | $1K – $15K |
| 2014-02-06 | Lamar Smith | buy | $1K – $15K |
| 2014-01-29 | MICHAEL T. MCCAUL | sell | $15K – $50K |
| 2013-12-19 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2013-12-19 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2013-12-19 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2013-12-16 | David P. Roe | sell | $1K – $15K |
| 2013-12-16 | David P. Roe | sell | $1K – $15K |
| 2013-12-16 | David P. Roe | buy | $1K – $15K |
| 2013-12-06 | Bradley S. Schneider | sell | $1K – $15K |